Ticagrelor use approved for high-risk CAD patients | Tracking prescription trends during the pandemic

Ticagrelor has been approved by the FDA for reducing the risk of a first heart attack or stroke in high-risk coronary artery disease (CAD) patients.

The use of hydroxychloroquine and chloroquine as potential COVID-19 treatments has been one of the pandemic’s biggest stories, with some studies revealing promise and others offering reasons for concern.

As protests continue throughout the world in the wake of George Floyd’s death, the Society of Thoracic Surgeons has issued a statement condemning racism and violence.

Hospitals throughout the United States have reported that a general fear of COVID-19 has led to significant drops in patients presenting with heart attack symptoms and other cardiovascular issues.

The emergency use authorization covers patients who experience right-sided heart failure following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.

The FDA is pushing for a voluntary recall of certain lots of extended-release metformin after lab tests revealed unacceptable levels of N-nitrosodimethylamine.

The investor-owned, Los Angeles-based giant said it’s also seeing imaging volumes rebound in many of its core markets.

Colorado State University and the University of Illinois at Urbana-Champaign teamed up to develop the harmonic optical tomography approach.